Status: Recruiting
Investigation of Small Mobile Stem Cells (SMS Cells) in Participants With Chronic Obstructive Pulmonary Disease (COPD).
This study is a phase 1, first-in-human, open-label, non-randomized, dose escalation safety study of 18 participants, between 39 and 69 years of age, with mild to moderate chronic obstructive pulmonary disease, treated with SORT-COPD (SMS cells). The primary objective of this study is to determine the safety of SORT-COPD (SMS cells) at three doses in people with chronic obstructive pulmonary disease.
Participants needed: 18
Trial details
Phase: Phase 1Age: 39-69Biological sex: AllType: InterventionalSponsor: SMSbiotechUpdated: Feb 12, 2026Locations: 2
Eligibility criteria
Aged 39 to 69 years (inclusive). [+5]
Previous or current diagnosis of COPD-G, COPD-D, COPD-I, COPD-A or COPD-U; asthm... [+18]